167 related articles for article (PubMed ID: 38314727)
1. S100b treatment overcomes RAGE signaling deficits in myoblasts on advanced glycation end-product cross-linked collagen and promotes myogenic differentiation.
Olson LC; Nguyen T; Sabalewski EL; Puetzer JL; Schwartz Z; McClure MJ
Am J Physiol Cell Physiol; 2024 Apr; 326(4):C1080-C1093. PubMed ID: 38314727
[TBL] [Abstract][Full Text] [Related]
2. S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration.
Riuzzi F; Sorci G; Beccafico S; Donato R
PLoS One; 2012; 7(1):e28700. PubMed ID: 22276098
[TBL] [Abstract][Full Text] [Related]
3. Advanced glycation end products inhibit proliferation and primary cilia formation of myoblasts through receptor for advanced glycation end products pathway.
Suzuki S; Hayashi T; Egawa T
Biochem Biophys Res Commun; 2023 Dec; 684():149141. PubMed ID: 37897908
[TBL] [Abstract][Full Text] [Related]
4. The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo.
Riuzzi F; Sorci G; Donato R
J Biol Chem; 2006 Mar; 281(12):8242-53. PubMed ID: 16407300
[TBL] [Abstract][Full Text] [Related]
5. Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding.
Sorci G; Riuzzi F; Arcuri C; Giambanco I; Donato R
Mol Cell Biol; 2004 Jun; 24(11):4880-94. PubMed ID: 15143181
[TBL] [Abstract][Full Text] [Related]
6. S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner.
Sorci G; Riuzzi F; Agneletti AL; Marchetti C; Donato R
J Cell Physiol; 2004 May; 199(2):274-83. PubMed ID: 15040010
[TBL] [Abstract][Full Text] [Related]
7. S100B protein regulates myoblast proliferation and differentiation by activating FGFR1 in a bFGF-dependent manner.
Riuzzi F; Sorci G; Donato R
J Cell Sci; 2011 Jul; 124(Pt 14):2389-400. PubMed ID: 21693575
[TBL] [Abstract][Full Text] [Related]
8. S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner.
Sorci G; Riuzzi F; Agneletti AL; Marchetti C; Donato R
Mol Cell Biol; 2003 Jul; 23(14):4870-81. PubMed ID: 12832473
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end-products induce skeletal muscle atrophy and dysfunction in diabetic mice via a RAGE-mediated, AMPK-down-regulated, Akt pathway.
Chiu CY; Yang RS; Sheu ML; Chan DC; Yang TH; Tsai KS; Chiang CK; Liu SH
J Pathol; 2016 Feb; 238(3):470-82. PubMed ID: 26586640
[TBL] [Abstract][Full Text] [Related]
10. Identification of pyridinoline, a collagen crosslink, as a novel intrinsic ligand for the receptor for advanced glycation end-products (RAGE).
Murakami Y; Fujino T; Kurachi R; Hasegawa T; Usui T; Hayase F; Watanabe H
Biosci Biotechnol Biochem; 2018 Sep; 82(9):1508-1514. PubMed ID: 29804507
[TBL] [Abstract][Full Text] [Related]
11. Methylglyoxal - an advanced glycation end products (AGEs) precursor - Inhibits differentiation of human MSC-derived osteoblasts in vitro independently of receptor for AGEs (RAGE).
Waqas K; Muller M; Koedam M; El Kadi Y; Zillikens MC; van der Eerden BCJ
Bone; 2022 Nov; 164():116526. PubMed ID: 35995334
[TBL] [Abstract][Full Text] [Related]
12. Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia.
Chiappalupi S; Sorci G; Vukasinovic A; Salvadori L; Sagheddu R; Coletti D; Renga G; Romani L; Donato R; Riuzzi F
J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):929-946. PubMed ID: 32159297
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products decrease collagen I levels in fibroblasts from the vaginal wall of patients with POP via the RAGE, MAPK and NF-κB pathways.
Chen YS; Wang XJ; Feng W; Hua KQ
Int J Mol Med; 2017 Oct; 40(4):987-998. PubMed ID: 28849117
[TBL] [Abstract][Full Text] [Related]
14. Skeletal muscle progenitors are sensitive to collagen architectural features of fibril size and cross linking.
Hu LY; Mileti CJ; Loomis T; Brashear SE; Ahmad S; Chellakudam RR; Wohlgemuth RP; Gionet-Gonzales MA; Leach JK; Smith LR
Am J Physiol Cell Physiol; 2021 Aug; 321(2):C330-C342. PubMed ID: 34191625
[TBL] [Abstract][Full Text] [Related]
15. Impaired oligodendrogenesis and myelination by elevated S100B levels during neurodevelopment.
Santos G; Barateiro A; Gomes CM; Brites D; Fernandes A
Neuropharmacology; 2018 Feb; 129():69-83. PubMed ID: 29126910
[TBL] [Abstract][Full Text] [Related]
16. RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth.
Riuzzi F; Sorci G; Donato R
Am J Pathol; 2007 Sep; 171(3):947-61. PubMed ID: 17640970
[TBL] [Abstract][Full Text] [Related]
17. Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.
Davis HM; Essex AL; Valdez S; Deosthale PJ; Aref MW; Allen MR; Bonetto A; Plotkin LI
Bone; 2019 Jul; 124():89-102. PubMed ID: 31028960
[TBL] [Abstract][Full Text] [Related]
18. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products.
Shanmugam N; Kim YS; Lanting L; Natarajan R
J Biol Chem; 2003 Sep; 278(37):34834-44. PubMed ID: 12837757
[TBL] [Abstract][Full Text] [Related]
19. Human muscle satellite cells show age-related differential expression of S100B protein and RAGE.
Beccafico S; Riuzzi F; Puglielli C; Mancinelli R; Fulle S; Sorci G; Donato R
Age (Dordr); 2011 Dec; 33(4):523-41. PubMed ID: 21140295
[TBL] [Abstract][Full Text] [Related]
20. Methylglyoxal and Advanced Glycation End products: Insight of the regulatory machinery affecting the myogenic program and of its modulation by natural compounds.
Baig MH; Jan AT; Rabbani G; Ahmad K; Ashraf JM; Kim T; Min HS; Lee YH; Cho WK; Ma JY; Lee EJ; Choi I
Sci Rep; 2017 Jul; 7(1):5916. PubMed ID: 28725008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
